Please login to the form below

Not currently logged in

Novel HIV treatment shows promise

Myriad Pharmaceuticals' HIV treatment MPC-4326 "safe and well tolerated"

Myriad Pharmaceuticals' HIV treatment MPC-4326 is safe and well tolerated according to two abstracts presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting on 12–15 September in San Francisco, US.

MPC-4326 is the first 'maturation inhibitor' a new class of HIV drug that inhibits the final step in the processing of the HIV Gag protein. Treatments with novel mechanism of action are though to be critical to combat drug resistance to available HIV therapies.

"I am very excited that the new 100 mg tablet formulation of MPC-4326 has performed so well," said Dr Adrian Hobden, President and CEO of the Salt Lake City-based biopharmaceutical company. "Coupled with the potential companion diagnostic and the significant viral load reductions seen in these two studies, we believe that we have a clear clinical path forward."

15th September 2009


Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?